Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Bloom's syndrome protein, BLM, is a member of the conserved RecQ helicase family. Although cell lines lacking BLM exist, these exhibit progressive genomic instability that makes distinguishing primary from secondary effects of BLM loss problematic. In order to be able to acutely disable BLM function in cells, we undertook a high throughput screen of a chemical compound library for small molecule inhibitors of BLM. We present ML216, a potent inhibitor of the DNA unwinding activity of BLM. ML216 shows cell-based activity and can induce sister chromatid exchanges, enhance the toxicity of aphidicolin, and exert antiproliferative activity in cells expressing BLM, but not those lacking BLM. These data indicate that ML216 shows strong selectivity for BLM in cultured cells. We discuss the potential utility of such a BLM-targeting compound as an anticancer agent.

Original publication

DOI

10.1016/j.chembiol.2012.10.016

Type

Journal article

Journal

Chem Biol

Publication Date

24/01/2013

Volume

20

Pages

55 - 62

Keywords

Antineoplastic Agents, Cell Line, Cell Proliferation, Chromosomal Instability, DNA, Enzyme Inhibitors, High-Throughput Screening Assays, Humans, Protein Binding, RecQ Helicases, Small Molecule Libraries